Drugs / VAX-24
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT05266456 | Feb 2022 → Jan 2023 | — | Vaxcyte, Inc. | Completed | Met primary |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05844423 | Mar 2023 → Aug 2025 | — | Vaxcyte, Inc. | Completed | Met primary |
| Phase 2 | NCT05297578 | Jun 2022 → Feb 2023 | — | Vaxcyte, Inc. | Completed | Mixed |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Vaxcyte, Inc. | Results Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study vaxcyte.com ↗
In this study, VAX-24 was well-tolerated and demonstrated a safety profile similar to PCV20 across all doses studied. |
| 2025-03-31 | Vaxcyte, Inc. | Results Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study vaxcyte.com ↗ |
| 2023-12-04 | Vaxcyte, Inc. | Results VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate vaxcyte.com ↗
All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards |
| 2023-04-17 | Vaxcyte, Inc. | Results Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies vaxcyte.com ↗
VAX-24 Showed Robust Immune Responses Across all 24 Serotypes (ST) at All Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 |
| 2023-02-27 | Vaxcyte, Inc. | Regulatory Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update vaxcyte.com ↗
Company Received U.S. Food and Drug Administration (FDA) Clearance of VAX-24 Infant Investigational New Drug (IND) Application and Expects to Initiate Phase 2 Study in Second Quarter 2023 |
| 2023-02-21 | Vaxcyte, Inc. | Regulatory Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants vaxcyte.com ↗
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s infant Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD). |
| 2023-01-05 | Vaxcyte, Inc. | Regulatory Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults vaxcyte.com ↗
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine (PCV) candidate for the prevention of invasive pneumococcal disease (IPD), in adults. |
| 2022-10-24 | Vaxcyte, Inc. | Results Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 vaxcyte.com ↗
In this study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to Prevnar 20 TM (PCV20) for all doses studied. |
| 2022-08-04 | Vaxcyte, Inc. | Regulatory Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs vaxcyte.com ↗
Company Receives FDA Fast Track Designation for VAX-24 in Adults |
| 2022-01-06 | Vaxcyte, Inc. | Regulatory Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease vaxcyte.com ↗
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease. |
| 2021-05-10 | Vaxcyte, Inc. | Results Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease vaxcyte.com ↗ |
All press releases naming this drug 21 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAX-24 | “VAX-24 is a 24-valent pneumococcal conjugate vaccine (PCV) containing eCRM, a proprietary carrier protein with non-native amino acids (para-azidomethyl-L-phenylalanine) that...” PMID 39025698 ↗ Jul 20242“We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197...” PMID 38061367 ↗ Dec 2023 |
| Known as | 24-valent pneumococcal conjugate vaccine | “We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197...” PMID 38061367 ↗ Dec 2023 |
| Modality | Vaccine | “We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine)” PMID 38061367 ↗ Dec 2023 |
| Route | Intramuscular | “Participants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.” NCT05266456 ↗ |